These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. N Engl J Med; 1987 Oct 08; 317(15):909-16. PubMed ID: 2442609 [Abstract] [Full Text] [Related]
12. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence. Capitanio U, Scattoni V, Freschi M, Briganti A, Salonia A, Gallina A, Colombo R, Karakiewicz PI, Rigatti P, Montorsi F. Eur Urol; 2008 Jul 08; 54(1):118-25. PubMed ID: 18314255 [Abstract] [Full Text] [Related]
13. Detection of prostatic carcinoma: the role of TRUS, TRUS guided biopsy, digital rectal examination, PSA and PSA density. Men S, Cakar B, Conkbayir I, Hekimoglu B. J Exp Clin Cancer Res; 2001 Dec 08; 20(4):473-80. PubMed ID: 11876539 [Abstract] [Full Text] [Related]
15. The association of prostate stem cell antigen (PSCA) mRNA expression and subsequent prostate cancer risk in men with benign prostatic hyperplasia following transurethral resection of the prostate. Zhigang Z, Wenlu S. Prostate; 2008 Feb 01; 68(2):190-9. PubMed ID: 18076024 [Abstract] [Full Text] [Related]
16. Incidence and factors predicting the detection of prostate cancer after transurethral resection of the prostate for clinically benign disease. Bright EA, Manuel C, Goddard JC, Khan MA. Urol Int; 2009 Feb 01; 83(2):171-4. PubMed ID: 19752612 [Abstract] [Full Text] [Related]